1. Mares-Segura R, Sola-Lamoglia R, Soler-Singla L, Pou-Serradell A. Guillain-Barré syndrome associated with hepatitis A. Ann Neurol. 1986. 19:100.
Article
2. Ono S, Chida K, Takasu T. Guillain-Barré syndrome following fulminant viral hepatitis A. Intern Med. 1994. 33:799–801.
3. Triggs WJ, Cros D, Gominak SC, Zuniga G, Beric A, Shahani BT, et al. Motor nerve inexcitability in Guillain-Barré syndrome. The spectrum of distal conduction block and axonal degeneration. Brain. 1992. 115:1291–1302.
Article
4. Vargas F, Hilbert G, Gruson D, Valentino R, Gbikpi-Benissan G, Cardinaud JP. Fulminant Guillain-Barré syndrome mimicking cerebral death: case report and literature review. Intensive Care Med. 2000. 26:623–627.
Article
5. Samantray SK, Johnson SC, Mathai KV, Pulimood BM. Landry-Guillain-Barré-Strohl syndrome. A study of 302 cases. Med J Aust. 1977. 2:84–91.
6. Dowling PC, Bosch VV, Cook SD. Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis. Neurology. 1980. 3033–3036.
Article
7. Mori E, Yoshida T, Ohsumi Y, Tabuchi M, Yamadori A. Beneficial effects of plasma exchange in acute Guillain-Barré syndrome: comparision with methylprednisolone pulse therapy. Clin Neurol. 1988. 28:196–203.
8. Ropper AH, Wijdicks EF, Truax BT. Guillain-Barré syndrome. 1991. Philadelphia: F.A. Davis;232–234. Contemporary Neurology Series.
9. Winer JB, Hughes RA, Greenwood RJ, Perkin GD, Healy MJ. Prognosis in Guillain-Barré syndrome. Lancet. 1985. 1:1202–1203.